Incidence of rash and discontinuation of nevirapine using two different escalating initial doses.
Antón
P
P
Soriano
V
V
Jiménez-Nácher
I
I
Rodriguez-Rosado
R
R
Dona
M C
MC
Barreiro
P M
PM
González-Lahoz
J
J
D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005076:Exanthema / Q000150:complications / Q000453:epidemiology*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D015497:HIV-1; D006801:Humans; D015994:Incidence; D019829:Nevirapine / Q000009:adverse effects* / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine